Literature DB >> 29160531

Lack of protocols for handling missing sessions of transcranial direct current stimulation (tDCS) in depression trials: what are the risks of neglecting missing sessions?

Rivadávio F Amorim1, Monique Gomes da Silva Scalco1,2, Maria Cecília de Freitas-Ferrari1,2, Tiago Freitas1, Heitor Moreno3, Aline Patrícia Brietzke4, Joaquim Brasil-Neto5.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 29160531      PMCID: PMC7111416          DOI: 10.1590/1516-4446-2017-2275

Source DB:  PubMed          Journal:  Braz J Psychiatry        ISSN: 1516-4446            Impact factor:   2.697


× No keyword cloud information.
Transcranial direct current stimulation (tDCS) represents a potential effective treatment for depression and has already shown encouraging results.1,2 Given that tDCS requires the subject’s presence, the probability of missed sessions is high, especially in depressed subjects. However, there is no consensus about the effects of missed sessions on tDCS efficacy. A recent study reported that 60% of depressive subjects in a tDCS study missed at least one visit out of ten.3 It is also known that the intensity and, probably, the frequency of tDCS sessions significantly increase the effectiveness of tDCS.3 Missing sessions are very frequent, and how to deal with them is an issue of high relevance. Unfortunately, there is a glaring lack of information about missed sessions in tDCS trials for depression, even though this can lead to possible changes in the results and their interpretation. Thus, we can infer that missing sessions is potentially harmful to a complete response by the depressed individual. We performed a systematic review of the PubMed/MEDLINE database between 2005 and 2015 regarding methods used to handle missing sessions in trials. Of the eight included trials, only three provided some information about missing sessions (Table 1). The two first trials4,5 mentioned the maximum number of sessions that could be missed (no more than two non-consecutive sessions) before excluding the subject and how they handled such cases. Zanão et al. stated that missing two sessions in the acute treatment phase might not change the final result, although they point out the need for more studies exploring the impact of a higher number of absences on the treatment of depression disorders. The management of this methodological issue is fundamental for scientific development.
Table 1

RCTs characteristics using tDCS for depression

StudySubjects(n)Current (mA)Duration (min)No. sessionsAnode/CathodeDropoutMissing sessionsPositive outcome
Fregni 20066 101205F3/RSO0NMYes
Boggio 20087 4022010F3/RSO0NMYes
Loo 20108 401205(10*)F3/RSO6NMYes
Brunoni 20134 12023012F3/F417Yes (>2 sessions)Yes
Brunoni 20145 3723010F3/F421Yes (>2 sessions)No
Ho 20149 1422010F3/F8 or F8/F32NMYes
Segrave 2014272245F3/F81Yes* Yes
Bennabi 201510 2423010F3/RSO1NMNo

NM= not mentioned; RSO = right supraorbital area; RCT = randomized controlled trial; tDCS = transcranial direct current stimulation.

Previous session result was reported when a patient missed one session.

Participants were allowed to miss two nonconsecutive visits; in such cases, extra tDCS sessions were performed to complete the total number of sessions.

Another question is whether there is a relation between the efficacy and timing of a missing session. Do subjects who missed sessions other than at the beginning of the trial have the same results? What about the lasting effects, are they affected by the timing of missing sessions as well? One study made up for the missed tDCS sessions at the end of the protocol.4 This evidently shows concern with the methodological approach but, again, leads us to question whether the results can be interpreted in the same way for these subjects. Segrave et al.11 considered the last observation carried forward as a way of dealing with the missing data due to missed sessions. This is a conservative method that can minimize the good results of tDCS. Moreover, details about how many subjects missed one or more sessions were not provided. The majority of the available articles made no mention of methodological concerns over this issue. Considering that depressed individuals have difficulty in performing their daily activities, not only having a well-designed plan to address missing sessions but also building an adaptive protocol requires urgent attention. Therefore, clear definitions about how to address them and well-designed guidelines are needed. A new trial specifically designed to assess tDCS efficacy according to the number of missing sessions would certainly help establish a comprehensive framework for informing how many sessions can be missed without having a major impact on the subject.

Disclosure

The authors report no conflicts of interest.
  11 in total

1.  Treatment of major depression with transcranial direct current stimulation.

Authors:  Felipe Fregni; Paulo S Boggio; Michael A Nitsche; Marco A Marcolin; Sergio P Rigonatti; Alvaro Pascual-Leone
Journal:  Bipolar Disord       Date:  2006-04       Impact factor: 6.744

Review 2.  Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data.

Authors:  André R Brunoni; Adriano H Moffa; Felipe Fregni; Ulrich Palm; Frank Padberg; Daniel M Blumberger; Zafiris J Daskalakis; Djamila Bennabi; Emmanuel Haffen; Angelo Alonzo; Colleen K Loo
Journal:  Br J Psychiatry       Date:  2016-04-07       Impact factor: 9.319

3.  Cognitive control therapy and transcranial direct current stimulation for depression: a randomized, double-blinded, controlled trial.

Authors:  A R Brunoni; P S Boggio; R De Raedt; I M Benseñor; P A Lotufo; V Namur; L C L Valiengo; M A Vanderhasselt
Journal:  J Affect Disord       Date:  2014-03-27       Impact factor: 4.839

4.  Transcranial direct current stimulation for the treatment of post-stroke depression: results from a randomised, sham-controlled, double-blinded trial.

Authors:  Leandro C L Valiengo; Alessandra C Goulart; Janaina F de Oliveira; Isabela M Benseñor; Paulo A Lotufo; Andre R Brunoni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-11-04       Impact factor: 10.154

5.  Concurrent cognitive control training augments the antidepressant efficacy of tDCS: a pilot study.

Authors:  R A Segrave; S Arnold; K Hoy; P B Fitzgerald
Journal:  Brain Stimul       Date:  2013-12-19       Impact factor: 8.955

6.  The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial.

Authors:  Andre R Brunoni; Leandro Valiengo; Alessandra Baccaro; Tamires A Zanão; Janaina F de Oliveira; Alessandra Goulart; Paulo S Boggio; Paulo A Lotufo; Isabela M Benseñor; Felipe Fregni
Journal:  JAMA Psychiatry       Date:  2013-04       Impact factor: 21.596

7.  A pilot study of alternative transcranial direct current stimulation electrode montages for the treatment of major depression.

Authors:  Kerrie-Anne Ho; Siwei Bai; Donel Martin; Angelo Alonzo; Socrates Dokos; Pablo Puras; Colleen K Loo
Journal:  J Affect Disord       Date:  2014-06-18       Impact factor: 4.839

8.  A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression.

Authors:  Paulo S Boggio; Sergio P Rigonatti; Rafael B Ribeiro; Martin L Myczkowski; Michael A Nitsche; Alvaro Pascual-Leone; Felipe Fregni
Journal:  Int J Neuropsychopharmacol       Date:  2007-06-11       Impact factor: 5.176

9.  A double-blind, sham-controlled trial of transcranial direct current stimulation for the treatment of depression.

Authors:  Colleen K Loo; Perminder Sachdev; Donel Martin; Melissa Pigot; Angelo Alonzo; Gin S Malhi; Jim Lagopoulos; Philip Mitchell
Journal:  Int J Neuropsychopharmacol       Date:  2009-08-12       Impact factor: 5.176

10.  Impact of two or less missing treatment sessions on tDCS clinical efficacy: results from a factorial, randomized, controlled trial in major depression.

Authors:  Tamires A Zanão; Adriano H Moffa; Pedro Shiozawa; Paulo A Lotufo; Isabela M Benseñor; André R Brunoni
Journal:  Neuromodulation       Date:  2014-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.